Last Updated : July 20, 2011
Details
FilesGeneric Name:
Zoledronic acid
Project Status:
Complete
Therapeutic Area:
Osteoporosis
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Aclasta
Project Line:
Reimbursement Review
Project Number:
SF0242-000
NOC Status at Filing:
Post NOC
Submission Type:
Request For Advice
Indications:
Osteoporosis (postmenopausal women)
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : July 20, 2011